Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease
Author(s) -
Rokhsara Rafii,
Timothy E. Albertson,
Samuel Louie,
Andrew L. Chan
Publication year - 2011
Publication title -
pulmonary medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.528
H-Index - 30
eISSN - 2090-1836
pISSN - 2090-1844
DOI - 10.1155/2011/257496
Subject(s) - medicine , copd , pulmonary rehabilitation , intensive care medicine , pharmacotherapy , wasting , pulmonary disease , smoking cessation , psychological intervention , disease , depression (economics) , palliative care , isolation (microbiology) , pathology , bioinformatics , psychiatry , macroeconomics , nursing , biology , economics
Chronic obstructive pulmonary disease (COPD) is a debilitating pulmonary disorder with systemic effects, and it is the fourth leading cause of death in the United States. COPD patients not only develop respiratory limitations, but can also demonstrate systemic wasting, features of depression, and can succumb to social isolation. Smoking cessation is crucial, and pharmacotherapy with bronchodilators is helpful in symptom management. Inhaled corticosteroids may be beneficial in some patients. In addition, pulmonary rehabilitation and palliative care are important components under the right clinical circumstance. This review highlights current guidelines and management strategies for COPD and emphasizes novel pharmacotherapy and minimally invasive (nonsurgical) lung-volume reduction interventions that may prove to be of significant benefit in the future.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom